

Accepted Manuscript

MT-ND5 Mutation Exhibits Highly Variable Neurological Manifestations at Low Mutant Load

Yi Shiau Ng, Nichola Z. Lax, Paul Maddison, Charlotte L. Alston, Emma L. Blakely, Philippa D. Hepplewhite, Gillian Riordan, Surita Meldau, Patrick F. Chinnery, Germaine Pierre, Efstathia Chronopoulou, Ailian Du, Imelda Hughes, Andrew A. Morris, Smaragda Kamakari, Georgia Chrousos, Richard J. Rodenburg, Christiaan G.J. Saris, Catherine Feeney, Steven A. Hardy, Takafumi Sakakibara, Akira Sudo, Yasushi Okazaki, Kei Murayama, Helen Mundy, Michael G. Hanna, Akira Ohtake, Andrew M. Schaefer, Mike P. Champion, Doug M. Turnbull, Robert W. Taylor, Robert D.S. Pitceathly, Robert McFarland, Gráinne S. Gorman



PII: S2352-3964(18)30064-1
DOI: doi:[10.1016/j.ebiom.2018.02.010](https://doi.org/10.1016/j.ebiom.2018.02.010)
Reference: EBIOM 1365
To appear in: *EBioMedicine*
Received date: 9 January 2018
Revised date: 3 February 2018
Accepted date: 12 February 2018

Please cite this article as: Yi Shiau Ng, Nichola Z. Lax, Paul Maddison, Charlotte L. Alston, Emma L. Blakely, Philippa D. Hepplewhite, Gillian Riordan, Surita Meldau, Patrick F. Chinnery, Germaine Pierre, Efstathia Chronopoulou, Ailian Du, Imelda Hughes, Andrew A. Morris, Smaragda Kamakari, Georgia Chrousos, Richard J. Rodenburg, Christiaan G.J. Saris, Catherine Feeney, Steven A. Hardy, Takafumi Sakakibara, Akira Sudo, Yasushi Okazaki, Kei Murayama, Helen Mundy, Michael G. Hanna, Akira Ohtake, Andrew M. Schaefer, Mike P. Champion, Doug M. Turnbull, Robert W. Taylor, Robert D.S. Pitceathly, Robert McFarland, Gráinne S. Gorman , MT-ND5 Mutation Exhibits Highly Variable Neurological Manifestations at Low Mutant Load. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. *Ebiom*(2017), doi:[10.1016/j.ebiom.2018.02.010](https://doi.org/10.1016/j.ebiom.2018.02.010)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The

manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

***MT-ND5* mutation exhibits highly variable neurological manifestations at low mutant load**

Yi Shiau Ng, PhD, MRCP^{1,*}; Nichola Z. Lax, PhD,^{1,*}; Paul Maddison, MD²; Charlotte L. Alston, PhD¹; Emma L. Blakely, PhD¹; Philippa D. Hepplewhite, BSc¹; Gillian Riordan, FCP³; Surita Meldau, MSc⁴; Patrick F. Chinnery, PhD, FRCP^{1,5}; Germaine Pierre, MSc⁶; Efstathia Chronopoulou, MRCPCH⁶; Ailian Du, PhD, MD¹⁷; Imelda Hughes, FRCPCH⁸; Andrew A. Morris, PhD⁹; Smaragda Kamakari, PhD¹⁰; Georgia Chrousos, MD¹¹; Richard J Rodenburg, PhD¹²; Christiaan G.J. Saris, PhD, MD¹³; Catherine Feeney, RGN¹; Steven A. Hardy, PhD¹; Takafumi Sakakibara, MD, PhD¹⁴; Akira Sudo, MD, PhD¹⁵; Yasushi Okazaki, MD, PhD¹⁶; Kei Murayama, MD, PhD¹⁷; Helen Mundy, MRCPCH¹⁸; Michael G. Hanna, MD, FRCP¹⁹; Akira Ohtake, MD, PhD²⁰; Andrew M Schaefer, MRCP¹; Mike P Champion, FRCPCH¹⁸; Doug M. Turnbull, PhD, FRCP¹; Robert W. Taylor, PhD, FRCPATH¹; Robert D.S. Pitceathly, PhD, MRCP¹⁹; Robert McFarland, PhD, MRCP, MRCPCH¹; Gráinne S. Gorman, PhD, FRCP¹

* These authors contributed equally.

¹Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

²Department of Neurology, Queen's Medical Centre, Nottingham, UK

³Paediatric Neurology Department, Red Cross War Memorial Children's Hospital, Cape Town, South Africa

⁴Division of Chemical Pathology, Faculty of Health Sciences, University of Cape Town, South Africa; National Health Laboratory Service, Cape Town, South Africa.

⁵Medical Research Council Mitochondrial Biology Unit, Cambridge Biomedical Campus, Cambridge, UK

⁶Department of Inherited Metabolic Disease, Division of Women's and Children's Services, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

⁷Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

⁸Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, United Kingdom.

⁹Institute of Human Development, University of Manchester, Manchester M13 9WL, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK.

¹⁰Ophthalmic Genetics Unit, OMMA, Institute of Ophthalmology, Athens, Greece.

¹¹Pediatric Ophthalmology Department, MITERA Children's Hospital, Athens, Greece.

¹²Radboud Center for Mitochondrial Medicine, Department of Pediatrics, Radboud University Medical Center, Nijmegen, The Netherlands

¹³Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.

¹⁴Department of Pediatrics, Nara Medical University Hospital, Nara 634-8522, Japan

¹⁵Department of Pediatrics, Sapporo City General Hospital, Sapporo 060-8604, Japan

¹⁶Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan

¹⁷Department of Metabolism, Chiba Children's Hospital, Chiba 266-0007, Japan¹⁸Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK.

¹⁹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK²⁰Department of Pediatrics, Faculty of Medicine, Saitama Medical University, Saitama 350-0495, Japan

Corresponding author

Dr Gráinne Gorman

Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

Phone: +441912820340; Fax: +441912824373

Email: grainne.gorman@ncl.ac.uk

Manuscript word count: 3355

Number of Tables: 2

Number of Figures: 3

Supplemental materials:

1. Supplemental data - Clinical vignettes
2. Supplemental figures (x3)
3. Supplemental tables (x2)

Abstract (196 words)

Mutations in the m.13094T>C *MT-ND5* gene have been previously described in three cases of Leigh Syndrome (LS). In this retrospective, international cohort study we identified 20 clinically affected individuals (13 families) and four asymptomatic carriers.. Ten patients were deceased at the time of analysis (median age of death was 10 years (range: 5·4 months - 37 years, IQR= 17·9 years). Nine patients manifested with LS, one with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), and one with Leber hereditary optic neuropathy. The remaining nine patients presented with either overlapping syndromes or isolated neurological symptoms. Mitochondrial respiratory chain activity analysis was normal in five out of ten muscle biopsies. We confirmed maternal inheritance in six families, and demonstrated marked variability in tissue segregation, and phenotypic expression at relatively low blood mutant loads. Neuropathological studies of two patients manifesting with LS/MELAS showed prominent capillary proliferation, microvacuolation and severe neuronal cell loss in the brainstem and cerebellum, with conspicuous absence of basal ganglia involvement. These findings suggest that whole mtDNA genome sequencing should be considered in patients with suspected mitochondrial disease presenting with complex neurological manifestations, which would identify over 300 known pathogenic variants including the m.13094T>C.

Keywords: Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS); Leigh syndrome (LS); mitochondrial DNA; heteroplasmy; neuropathology

INTRODUCTION

Defects in oxidative phosphorylation (OXPHOS) are an important cause of human morbidity and mortality, with complex I (NADH-ubiquinone oxidoreductase) deficiency recognized as the most commonly observed OXPHOS defect.¹ Complex I (NADH: ubiquinone oxidoreductase) is the largest component of the oxidative phosphorylation system (OXPHOS) composed of 45 subunits that, in supercomplex formation with respiratory chain complexes III and IV, drives the generation of a transmembrane protein gradient powering adenosine triphosphate (ATP) synthesis. Complex I requires 14 evolutionary conserved core subunits for its catalytic function: seven mtDNA-encoded NADH-dehydrogenase (ND) core subunits (ND1-6, ND4L) and seven nuclear DNA (nDNA) encoded subunits (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7 and NDUFS8), in addition to 31 supernumerary subunits, whose exact roles are yet to be fully defined.² The *MT-ND5* gene of complex I, appears to be a mutational ‘hot spot’³ and linked to a variety of clinical phenotypes ranging from single organ involvement, such as isolated exercise intolerance⁴ or Leber hereditary optic neuropathy (LHON),⁵ to multisystem disease manifesting as renal failure and myopathy,⁶ Leigh syndrome (LS),^{7,8} mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS),^{9,10} or as a combination of overlapping syndromes including LS/MELAS,^{7,11} MELAS/myoclonic epilepsy and ragged red fibres (MERRF),¹² LHON/MELAS¹³ and LS/MELAS/LHON.¹⁰ The limited understanding of the natural history of disease caused by such mutations presents significant challenges in clinical practice, particularly in relation to pre-symptomatic genetic testing of at-risk family relatives.

The m.13094T>C mutation, in the *MT-ND5* gene, is considered a rare pathogenic variant that has been previously reported in association with LS but the full phenotypic spectrum has remained poorly understood.^{14,15} We present the clinical, radiological, and histopathological data of 24 subjects who harbor the m.13094T>C mutation. We have also

studied the neuropathological changes in two patients with LS/MELAS overlap syndrome, to fully elucidate the spectrum of m.13094T>C-related mitochondrial disease and to offer guidance on management and genetic counseling.

MATERIALS AND METHODS

Study design and patients

This retrospective, international cohort study was done at the NHS Highly Specialised Service-funded Mitochondrial Diagnostic Centers in Newcastle upon Tyne and London, UK. These included patients referred from four other countries: China, South Africa, Greece and Japan. Eligible participants were genetically confirmed to harbor the m.13094T>C mutation (p.Val253Ala) in *MT-ND5* over a 17 year period (January 2000 – October 2017); their maternal family members were traced and examined whenever possible.

This study was approved and performed under the ethical guidelines issued by our institution for clinical studies, and complied with the declaration of Helsinki.

Clinical Presentation and Phenotypic Evaluation

Each patient was assessed by a specialist (pediatrician, adult neurologist and/or ophthalmologist) at each center, and their medical records were comprehensively reviewed. The clinical presentation of individual patients and their family pedigree are provided in **Supplemental data and Supplemental Figure 1**. Where possible, common clinical syndromes described in mitochondrial disease were assigned (and agreed by all authors).

Histopathological and Biochemical Studies

Standard histological (hematoxylin and eosin (H&E) and modified Gomori Trichome stains), histochemical (cytochrome c oxidase (COX), succinate dehydrogenase (SDH), and sequential

COX–SDH and biochemical assessments of muscle tissue were performed as described elsewhere (**Supplemental Table 1**). Fresh tissue was fixed in 2.5% glutaraldehyde buffered to pH 7.4 with phosphate buffer and post-fixed in OsO₄ and embedded in Epon LX-112. Ultra-thin sections were examined in an electron microscope (JEOL-1500, Japan) for Patient 5.

Molecular Genetics

Extraction of total DNA was performed as per standard procedure. The whole mitochondrial genome was sequenced, and pyrosequencing assay was used¹⁶ to screen for and quantify the m.13094T>C mutation (GenBank Accession number: NC_012920.1) for 13 patients (Patients 1, 1.1, 1.2, 2, 2.1, 2.2, 2.4, 3, 3.1, 4, 6, 8 and 8.1). The assay could reliably detect a level of >3% of mutant mtDNA. Restriction fragment length polymorphism (RFLP) analysis was performed to quantify the m.13094T>C heteroplasmy level in Patients 5, 12 and 13, with the sensitivity of ~5%.¹⁴ The mutant heteroplasmy level was quantified using next-generation sequencing (NGS) for Patients 7, 7.1, 7.2, 9 and 10 (sensitivity >10%).

Neuropathological Studies

Neuropathological investigations were performed on postmortem brain tissues from two patients (patients 1.2 and 8). Cresyl fast violet (CFV), H&E and Luxol fast blue with H&E counterstain were used on formalin-fixed paraffin-embedded tissues to determine neuronal population density and degree of myelination. Immunohistochemistry to determine the expression levels of mitochondrial respiratory chain subunits, including complex I subunit NADH: ubiquinone oxidoreductase subunit B8 (NDUFB8) and complex II subunit succinate dehydrogenase subunit A (SDHA), were performed on 5 micron thick sections as previously described.¹⁷

Statistical Analysis

Non-parametric, continuous data were presented as median (range and inter-quartile range (IQR)). Correlation of mtDNA heteroplasmy level of different tissues and age of disease onset was examined using Spearman rank correlation test. Statistical significance was determined at $p < 0.05$. Data were managed and analyzed with IBM SPSS for Windows version 22.

RESULTS

Patient Cohorts

Clinical features of 24 individuals from 13 families are summarised in **Table 1**. The median age of disease onset was 5.5 years (n=20, range: 6 weeks to 34 years, IQR= 13years; the age of onset not known for two patients). Four individuals were clinically unaffected; they were ascertained pre-symptomatically due to diagnosis in other family members. Ten patients (42%) were deceased, and the median age of death was 10 years (range: 5.4 months to 37 years, IQR= 17.9 years).

Eleven patients presented with distinctive clinical syndromes previously described in mitochondrial disease. However, the remaining patients (n=9) manifested with an isolated neurological symptom or overlapping syndromes, of which central nervous system was most commonly affected (**Table 1**). Centrally mediated respiratory failure or apnoea was documented in nine patients (38%) with LS, including an adult patient who presented at the age of 22 years (Patient 10). Refractory focal onset seizures with or without evolution to bilateral convulsions occurred in eight patients (35%).

Radiological Imaging

Cranial magnetic resonance imaging (MRI) was available for analysis in 17 patients (**Table 2, Figure 1 and Supplemental Figure 2**). The most common T2/FLuid Attenuation Inversion Recovery (FLAIR)-signal abnormalities were present in the midbrain (n=12) and thalamus (n=9: bilateral, symmetrical changes; n=3: unilateral) followed by pons (n=10) and medulla (n=9). Brainstem changes in two patients (Patients 6 and 8), initially was initially misdiagnosed as a low-grade glioma, although gadolinium-enhancement was absent. Subacute cortical and subcortical signal changes were identified in six patients that were consistent with stroke-like lesions. Two patients had multiple cortical lesions including lesions within the cerebellar hemispheres (Patients 1.2 and 5), suggestive of cross cerebellar diaschisis. Cervical cord lesions were also identified in six patients.

Signal abnormalities within the basal ganglia, classically seen in LS, were only identified in two patients (Patients 11 and 13).

Histopathological and Biochemical Analyses

Histopathological and histochemical evaluation was normal in most patients except minor changes detected in the skeletal muscle of three patients: minor ragged red fibers (n=1), lipid droplets and abnormal mitochondrial ultrastructure (n=1) and occasional angular atrophic fibers (n=1). Mitochondrial respiratory chain activity was measured in skeletal muscle tissue from 10 patients. One patient demonstrated isolated complex I deficiency, one patient with combined complex I and III deficiencies, two patients with combined complex I and IV deficiencies and one patient had low complex I and II activity in postmortem tissue, which was caused by significant delay in tissue handling. The remaining six cases demonstrated normal respiratory chain activity (**Supplemental Table 1**).

Molecular Genetics

Thirteen probands were identified to harbor the m.13094T>C mutation through whole mtDNA sequencing after screening negative for common mtDNA point mutations including m.3243A>G, m.8344A>G, *MTATP6*, and *MTATP8* genes. The mutation was identified in nine individuals by direct sequencing of the mtDNA point mutation through pedigree and segregation analysis. Maternal inheritance of the m.13094T>C mutation was confirmed in six family pedigrees. The m.13094T>C mutation was not detected in the blood of Patient 1 (measured at age 37 years) with a severe, adult-onset MELAS phenotype although was detected at 51% in urine. Patient 2.2 was presumed an obligate carrier even though the m.13094T>C mutation was not detectable in blood (measured at age 74 years). There was no tissue sample available for testing in Patient 2.3. The asymptomatic mother of patient 3 was demonstrated to harbor the m.13094T>C mutation at mtDNA heteroplasmy levels of 19%, 27% and 45% in blood, muscle, and urine respectively (measured at age 24 years). The quantification of mutant mtDNA heteroplasmy level was not performed in two patients due to no access to tissue samples (Patient 2.3) and only Sanger sequencing was performed in Patient 11 (the mutant load in muscle appeared higher than blood; sensitivity >25%).

There was a statistically significant negative correlation between blood mtDNA heteroplasmy level and age (Spearman rho= -0.883, $p < 0.001$; **Figure 2A**). Among the patients with mutant mtDNA load quantified in more than one tissue (n=12), the mutant heteroplasmy levels in muscle (65% +/- 20%; n=10) and/or urine (40% +/- 27%; n=8) were consistently higher than blood (24% +/- 22%; n=16) (**Figure 2B**). The discrepancy between muscle and blood mtDNA heteroplasmy ranged from 3 to 75% in seven patients; the discrepancy between urine and blood mtDNA heteroplasmy levels ranged from 5 to 51% in

seven patients. Whole exome sequencing (methods described elsewhere¹⁸) was performed to investigate the cause of optic neuropathy in Patient 7. This excluded other known causative genes (including *OPA1*).

The m.13094T>C mutation load of a number of post-mortem tissues was analyzed from Patients 1.2 and 13 exemplifying the varied tissue segregation that is characteristic of this mtDNA mutation (**Table 3**). The m.13094T>C mutation load was specifically determined in brain homogenate samples from patients 1.2 and 8 demonstrating lower mutant load within neuronal tissues (median= 61%, range: 47-69%) compared to other tissues despite both manifesting with extensive neurological sequelae (**Table 3**).

Muscle (Spearman rho=0.192, p= 0.62) and urine (Spearman rho= -0.80, p= 0.20) mutant mtDNA heteroplasmy levels did not correlate with the age of disease onset. There was no significant difference in mean mutant heteroplasmy level in different syndromic categories (p=0.122).

Neuropathological Findings

The major neuropathological findings for patients 1.2 and 8 are summarised in **Supplemental Table 2**). In patient 1.2, posterior cerebellar cortex demonstrated multiple areas of necrotic lesions ranging from atrophy of the molecular layer, Purkinje cell dropout and granule cell loss (**Figure 3A**), to total necrosis of the cerebellar cortex that also affected the underlying white matter (**Figure 3B**). Concerning topographical distribution, lesions were most severe in the brainstem nuclei (**Figure 3C and D**), the thalamic and subthalamic nuclei (**Figure 3E and F**) and primary visual cortex (Brodmann area 17) (**Figure 3G**). At a microscopic level, changes such as prominent capillary proliferation, microvacuolation and severe neuronal loss were frequently observed in fixed cerebral and cerebellar hemispheres, and right brainstem

compatible with LS. Downregulation of complex I subunit (NDUFB8) was evident in the in the pons and cerebellar cortex of patient 1.2, and lesioned thalamus and occipital cortex of patient 8 (Supplemental Figure 3).

DISCUSSION

In this study, we have identified marked clinical heterogeneity with a continuous spectrum of overlapping symptoms associated with the m.13094T>C mutation. However within that clinical heterogeneity, at certain points in the course of disease, several distinct clinical syndromes associated with mutations in the *MT-ND5* gene were clearly discernible: early onset LS (38%), late childhood/early adulthood-onset LS/MELAS overlap syndrome (13%) and LHON (4%) (not previously recognized in association with the m.13094T>C mutation). LS frequently manifested with a typical illness trajectory including hypotonia, cranial nerve palsies, cerebellar ataxia, and developmental regression; with relapses in clinical status often triggered by inter-current illness. Brainstem dysfunction (manifesting as centrally-mediated respiratory failure and lability in blood pressure), commonly occurred as a pre-terminal event. Patients with the LS/MELAS overlap syndrome typically presented with refractory focal seizures and stroke-like lesions (as classically seen in MELAS). Additional features of brainstem dysfunction, including acute-onset ptosis, a complex eye movement disorder and worsening ataxia (as classically seen in LS) were not infrequent. Neuropsychiatric symptoms such as excessive anxiety, low mood, and hypersomnolence, in addition to cognitive impairment were features accompanying stroke-like episodes. A progressive gait disorder with truncal ataxia was a prominent clinical feature in three adult patients (13%), and additional neurological features such as strabismus (Patient 2.4), axonal neuropathy and stroke-like episode (Patient 2) were identified. Interestingly, optic neuropathy was the first clinical manifestation in four patients (Patients 1, 2.4, 7 and 7.1); however, additional severe central nervous system (CNS) involvement evolved in two patients (Patients 1 and 2.4).

These findings highlight that as the disease progressed, discrete syndromes were no longer discernible. Indeed, the heterogeneity of the neurological manifestations in the m.13094T>C mutation appears similar to that observed in other mtDNA encoded complex I gene mutations.

The most common T2/FLAIR signal abnormalities on cranial MRI were localized to the brainstem (71%), thalamus (71%), cerebral cortex (35%) and cervical cord (31%) and medial thalamic changes (with restricted diffusion) were identified in seven out of eight patients presenting with refractory epilepsy. Such findings suggest prolonged seizure activity (focal status epilepticus) as the underlying pathophysiological mechanism of the radiological (and clinical) changes observed.¹⁹ MRI abnormalities in cortical and/or subcortical areas, cerebellar hemispheres (crossed cerebellar diaschisis, which refers to cerebellar hypometabolism is ascribed to functional disconnection of the contralateral hemisphere from the cerebral cortex)²⁰ corpus callosum, thalami and basal ganglia have been increasingly reported in cases of isolated seizures, seizure clusters, and status epilepticus.¹⁹ Moreover, the development of cognitive dysfunction in these patients may be explained by the observed involvement of the cerebello-thalamo-cortical pathway (white matter tracts connecting the cerebellar cortex to the contralateral various cerebral cortices, passing through the superior cerebellar peduncle, red nuclear and the thalamus).²¹ T2/FLAIR signal abnormality involving the brainstem extending into the upper cervical cord was identified in four patients. Interestingly, Patient 5 had quite extensive T2/FLAIR signal changes spanning from C2 to C6, mimicking a demyelinating disorder but CSF restricted oligoclonal bands and anti-aquaporin 4 antibodies both tested negative. Whilst MR imaging findings are consistent with previously documented changes in other complex I deficient patients, it is striking that only two patients with the m.13094T>C mutation had evidence of striatal lesions¹⁴ compared to 90% of complex I cases reported by Lebre and colleagues.²² These findings are corroborated

by relative preservation of the striatum and the presence of devastating destruction of the thalami and brainstem with marked capillary proliferation on autopsy examination. Whilst symmetrical signal abnormalities in basal ganglia are the most common radiological finding in patients affected by LS, lesions may merely be confined to the brainstem^{23,24}, as was observed in all our cases. This again serves as a reminder that the diagnosis of LS (including due to *MT-ND5* mutations) should be considered even in the absence of symmetrical basal ganglia lesions.

The radiological appearances of patients with LS harboring the m.13094T>C mutation bear similarities to mitochondrial diseases caused by autosomal recessive tRNA synthetase mutations, such as leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL) caused by *EARS2* mutations and leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) caused by *DARS2* mutations.²⁵ In two of our cases, the radiological diagnosis was thought to be a space-occupying lesion at presentation. However, the 'relapsing-remitting' course of neurological deficits associated with m.13094T>C-related mitochondrial disease, coupled with the evolution of signal abnormalities on interval brain imaging and demonstration of abnormal signals in different regions of structurally normal brain on T1 images (but abnormal cerebral metabolism on MR spectroscopy), should aid clinicians to discern between the two conditions.

The clinical features of these patients may also overlap at various stages of the disease with other more common forms of mitochondrial disease, such as LHON, *OPA1*, and *POLG*-related disease, and may mimic other forms of hereditary ataxia. In addition, m.13094T>C-related mitochondrial disease may mimic inflammatory CNS disorders such as acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS) and neuromyelitis optica (Patients 5, 6 and 7). Indeed, the link of an MS-like illness and common LHON mutations is

well recognized in Harding disease, where imaging appearances are frequently indistinguishable from MS.²⁶ More recently, the coincidental occurrence of an MS-like disorder and *OPA1* mutations in three unrelated patients has also been reported.²⁷

We observed that the histochemical changes such as ragged red and COX deficient fibres, and biochemical analysis of mitochondrial respiratory chain activity in muscle tissue, was normal in 60% of the cases presented here, similar to other point mutations in *MT-ND5*.^{8,10,11} In addition, the quadruple immunohistochemistry technique could not detect the reduction of complex I subunit in muscle tissue in one of our patients,²⁸ in accordance with the findings of preferential CNS manifestations in association with this mutation. Interestingly, the threshold level of mutant mitochondrial load necessary to cause symptoms in these cases appears to be much lower than in mitochondrial tRNA gene-related disorders associated with severe clinical phenotypes. However, our findings corroborate previous findings in transmitochondrial cybrid models of the m.13094T>C mutation.¹⁴ Furthermore, severe clinical phenotypes associated with a relatively low mutant load have also been observed in other common point mutations in the *MT-ND5* gene, including the m.13513G>A mutation, where a mutant load of less than 50% in muscle has been reported in association with LS⁸ and MELAS.⁹ Preliminary pedigree analysis did not *initially* prove informative; however, extensive segregation testing confirmed this to be a maternally inherited genetic disorder. In addition, our findings highlight the importance of recognizing that mtDNA disease can only be definitively excluded by performing whole mitochondrial genome sequencing in post-mitotic tissues, such as muscle. In the case of predictive testing, we would advocate screening for the m.13094T>C mutation in muscle and/or urine to minimize the chance of false-negative results. The variable tissue segregation was further evident and exemplified by the variable mutation load in multiple tissues at autopsy (Patients 1.2 and 13). Intriguingly, the variable phenotypic threshold effect associated with the m.13094T>C

mutation would support the assertion that *MT-ND5* synthesis is a rate limiting step for complex I activity²⁹, given the relatively low mutant load resulting in severe phenotypic expression.⁷ Although we do not have serial measurements of the m.13094T>C mutant load in blood for individual patients, our data suggest that mutant mtDNA heteroplasmy level may decline with age, and we would hypothesize that there is a negative selection of this mutant mtDNA in bone marrow over time, as demonstrated in other commoner mtDNA mutations such as m.3243A>G and m.13513G>A. However, we concede there is a possibility of ascertainment bias in the older individuals with lower mutant heteroplasmy levels.

Patients 1.2 and 8 had MELAS/LS overlapping syndrome whilst Patient 13 had LS only. Patient 1.2 predominantly manifested with a childhood onset CNS disorder, with no evidence of myopathy (on clinical examination), cardiomyopathy, renal impairment or hepatic disease. However, in Patient 1.2, the mutant heteroplasmy levels were much higher in skeletal muscle (88%), heart (75%), kidney (83%) and liver (83%) compared to CNS tissues (~67%). Only patient 8 manifested with stroke-like episodes and subsequently a brainstem crisis in her 30s, yet the mutant mtDNA heteroplasmy levels in CNS tissues (~52%) were lower than in Patient 1.2. The tissue specificity of phenotypic expression in this mutation is intriguing, and the possible underlying reasons require further elucidation yet support the observation that mutant heteroplasmy level alone does not fully explain clinical manifestation.³⁰

In summary, the m.13094T>C mutation exhibits highly variable neurological manifestations and is frequently associated with high disease burden and early mortality. Cortico-thalamic-cerebellar involvement appears to be a frequent finding in these patients compared to other rare mtDNA mutations, and may serve as a radiological biomarker of m.13094T>C – related mitochondrial disease. Moreover, our findings would suggest m.13094T>C–related mitochondrial disease is perhaps not as rare as originally thought. We

would suggest that consideration should be given to screening the whole mtDNA genome in clinically relevant tissues, prior to proceeding to whole exome sequencing, in those who have tested negative for the commonly recognized disease causing genes and mtDNA point mutations. Once again, the observed clinical heterogeneity, often apparent lack of maternal inheritance, normal histological and biochemical muscle biopsy findings, and variability in tissue segregation in these cases, highlights the diagnostic challenges of mitochondrial disease caused by rare mtDNA variants. We suggest, these findings support a better understanding of m.13094T>C –related syndromes and their inherent clinical trajectory and as such will serve to aid a more timely diagnosis, inform accurate genetic counseling, and facilitate tailored therapeutic interventions.

Acknowledgements

We are extremely grateful to the patients and their families who have been instrumental in the conduct of this study. We wish also to acknowledge the work performed by members of the MRC Mitochondrial Disease Patient Cohort and staff of the NHS Highly Specialised Mitochondrial Disease Service laboratory in Newcastle. We would like to thank Dr. Minxin Guan from Institute of Genetics, Zhejiang University School of Medicine for performing the full length sequencing of mtDNA in Patient 5. We are also grateful for the clinical and diagnostic input from Professor Yu-ichi Goto from the Department of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry; Drs. Yukiko Yatsuka, Masakazu Kohda and Yoshihito Kishita from the Diagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Funding sources

This work was supported by The Wellcome Trust (203105), Newcastle University Centre for Ageing and Vitality (supported by the Biotechnology and Biological Sciences Research Council and Medical Research Council L016354), UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust, National Institute for Health Research (NIHR) and the UK NHS Specialist Commissioners which funds the “Rare Mitochondrial Disorders of Adults and Children” Diagnostic Service in Newcastle upon Tyne (<http://www.newcastle-mitochondria.com/>). This work also received infrastructure support from the UK Medical Research Council (MRC) Centre Mitochondrial Disease Patient Cohort: A Natural History Study and Patient Registry (REC ref 13/NE/0326), NIHR Biomedical Research Centre, Newcastle and North Tyneside Comprehensive Local Research Network. YSN currently holds an NIHR Clinical Lectureship in Neurology, and was previously funded by the MRC Centre of Neuromuscular diseases for his PhD study (MR/K000608/1). C.L.A is the recipient of a National Institute for Health Research (NIHR) doctoral fellowship (NIHR-HCS-D12-03-04). R.D.S.P. and M.G.H. are supported by a Medical Research Council Centre grant (G0601943). Part of this work was undertaken in the University College London Hospitals/University College London Institute of Neurology sequencing facility, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. Y.O. and A.O. are supported by both Strategic Research Center in Private Universities from the Japanese Ministry of Education, Culture, Sports, Science and Technology and Practical Research Project for Rare/Intractable Diseases from Agency for Medical Research and Development (AMED). K.M. is supported by AMED.

Our funding sources do not play any role in the writing of the manuscript or the decision to submit it for publication. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Declaration of interest

Nothing to report.

Author contributions

Conception and design of the study: Y.S.N., D.M.T., R.W.T., R.M. and G.S.G.

Acquisition of data: All authors

Analysis and interpretation of data: Y.S.N., N.Z.L., G.S.G.

Drafting the manuscript or figures: Y.S.N., N.Z.L., R.M., R.W.T., D.M.T., R.D.S.P., R.M. and G.S.G.

Critical review and revision: All authors

Authorship: Y.S.N. and N.L. are joint first authors.

Research in context

The m.13094T>C mutation in *MT-ND5* was considered a rare cause of mitochondrial disease that had been previously reported in association with Leigh Syndrome only. This study revealed that the m.13094T>C mutation is associated with severe, variable neurological features, with a more extensive phenotypic spectrum of disease, frequently manifesting at lower mutant heteroplasmy levels compared to many other primary mitochondrial DNA mutations. The work described here proposes that an unexplained central nervous system disorder should raise clinical suspicion of a mitochondrial disorder, and full mtDNA genome sequencing should be considered even with normal muscle biopsy findings.

References

1. Rodenburg RJ. Mitochondrial complex I-linked disease. *Biochimica et biophysica acta* 2016; **1857**(7): 938-45.
2. Zhu J, Vinothkumar KR, Hirst J. Structure of mammalian respiratory complex I. *Nature* 2016; **536**(7616): 354-8.
3. Bannwarth S, Procaccio V, Lebre AS, Jardel C, Chaussenot A, Hoarau C, Maoulida H, Charrier N, Gai X, Xie HM, Ferre M, Fragaki K, Hardy G, Mousson de Camaret B, Marlin S, Dhaenens CM, Slama A, Rocher C, Paul Bonnefont J, Rotig A, Aoutil N, Gilleron M, Desquret-Dumas V, Reynier P, Ceresuela J, Jonard L, Devos A, Espil-Taris C, Martinez D, Gaignard P, Le Quan Sang KH, Amati-Bonneau P, Falk MJ, Florentz C, Chabrol B, Durand-Zaleski I, Paquis-Flucklinger V. Prevalence of rare mitochondrial DNA mutations in mitochondrial disorders. *J Med Genet* 2013; **50**(10): 704-14.
4. Downham E, Winterthun S, Nakkestad HL, Hirth A, Halvorsen T, Taylor RW, Bindoff LA. A novel mitochondrial ND5 (MTND5) gene mutation giving isolated exercise intolerance. *Neuromuscular disorders : NMD* 2008; **18**(4): 310-4.
5. Howell N, Halvorson S, Burns J, McCullough DA, Paulton J. When does bilateral optic atrophy become Leber hereditary optic neuropathy? *American journal of human genetics* 1993; **53**(4): 959-63.
6. Alston CL, Morak M, Reid C, Hargreaves IP, Pope SA, Land JM, Heales SJ, Horvath R, Mundy H, Taylor RW. A novel mitochondrial MTND5 frameshift mutation causing isolated complex I deficiency, renal failure and myopathy. *Neuromuscular disorders : NMD* 2010; **20**(2): 131-5.
7. Blok MJ, Spruijt L, de Coo IF, Schoonderwoerd K, Hendrickx A, Smeets HJ. Mutations in the ND5 subunit of complex I of the mitochondrial DNA are a frequent cause of oxidative phosphorylation disease. *J Med Genet* 2007; **44**(4): e74.

8. Kirby DM, Boneh A, Chow CW, Ohtake A, Ryan MT, Thyagarajan D, Thorburn DR. Low mutant load of mitochondrial DNA G13513A mutation can cause Leigh's disease. *Annals of neurology* 2003; **54**(4): 473-8.
9. Shanske S, Coku J, Lu J, Ganesh J, Krishna S, Tanji K, Bonilla E, Naini AB, Hirano M, DiMauro S. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome: evidence from 12 cases. *Archives of neurology* 2008; **65**(3): 368-72.
10. Liolitsa D, Rahman S, Benton S, Carr LJ, Hanna MG. Is the mitochondrial complex I ND5 gene a hot-spot for MELAS causing mutations? *Annals of neurology* 2003; **53**(1): 128-32.
11. Crimi M, Galbiati S, Moroni I, Bordoni A, Perini MP, Lamantea E, Sciacco M, Zeviani M, Biunno I, Moggio M, Scarlato G, Comi GP. A missense mutation in the mitochondrial ND5 gene associated with a Leigh-MELAS overlap syndrome. *Neurology* 2003; **60**(11): 1857-61.
12. Naini AB, Lu J, Kaufmann P, Bernstein RA, Mancuso M, Bonilla E, Hirano M, DiMauro S. Novel mitochondrial DNA ND5 mutation in a patient with clinical features of MELAS and MERRF. *Archives of neurology* 2005; **62**(3): 473-6.
13. Pulkes T, Eunson L, Patterson V, Siddiqui A, Wood NW, Nelson IP, Morgan-Hughes JA, Hanna MG. The mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS. *Annals of neurology* 1999; **46**(6): 916-9.
14. Valente L, Piga D, Lamantea E, Carrara F, Uziel G, Cudia P, Zani A, Farina L, Morandi L, Mora M, Spinazzola A, Zeviani M, Tiranti V. Identification of novel mutations in five patients with mitochondrial encephalomyopathy. *Biochimica et biophysica acta* 2009; **1787**(5): 491-501.

15. Ching CK, Mak CM, Au KM, Chan KY, Yuen YP, Yau EK, Ma LC, Chow HL, Chan AY. A patient with congenital hyperlactataemia and Leigh syndrome: an uncommon mitochondrial variant. *Hong Kong Med J* 2013; **19**(4): 357-61.
16. Blakely EL, Yarham JW, Alston CL, Craig K, Poulton J, Brierley C, Park SM, Dean A, Xuereb JH, Anderson KN, Compston A, Allen C, Sharif S, Enevoldson P, Wilson M, Hammans SR, Turnbull DM, McFarland R, Taylor RW. Pathogenic mitochondrial tRNA point mutations: nine novel mutations affirm their importance as a cause of mitochondrial disease. *Human mutation* 2013; **34**(9): 1260-8.
17. Lax NZ, Hepplewhite PD, Reeve AK, Nesbitt V, McFarland R, Jaros E, Taylor RW, Turnbull DM. Cerebellar ataxia in patients with mitochondrial DNA disease: a molecular clinicopathological study. *Journal of neuropathology and experimental neurology* 2012; **71**(2): 148-61.
18. Neveling K, Feenstra I, Gilissen C, Hoefsloot LH, Kamsteeg EJ, Mensenkamp AR, Rodenburg RJ, Yntema HG, Spruijt L, Vermeer S, Rinne T, van Gassen KL, Bodmer D, Lugtenberg D, de Reuver R, Buijsman W, Derks RC, Wieskamp N, van den Heuvel B, Ligtenberg MJ, Kremer H, Koolen DA, van de Warrenburg BP, Cremers FP, Marcelis CL, Smeitink JA, Wortmann SB, van Zelst-Stams WA, Veltman JA, Brunner HG, Scheffer H, Nelen MR. A post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. *Human mutation* 2013; **34**(12): 1721-6.
19. Katramados AM, Burdette D, Patel SC, Schultz LR, Gaddam S, Mitsias PD. Periaxial diffusion abnormalities of the thalamus in partial status epilepticus. *Epilepsia* 2009; **50**(2): 265-75.
20. Tien RD, Ashdown BC. Crossed cerebellar diaschisis and crossed cerebellar atrophy: correlation of MR findings, clinical symptoms, and supratentorial diseases in 26 patients. *AJR American journal of roentgenology* 1992; **158**(5): 1155-9.
21. Palesi F, Tournier JD, Calamante F, Muhlert N, Castellazzi G, Chard D, D'Angelo E, Wheeler-Kingshott CA. Contralateral cerebello-thalamo-cortical pathways with prominent

- involvement of associative areas in humans in vivo. *Brain Struct Funct* 2015; **220**(6): 3369-84.
22. Lebre AS, Rio M, Faivre d'Arcier L, Vernerey D, Landrieu P, Slama A, Jardel C, Laforet P, Rodriguez D, Dorison N, Galanaud D, Chabrol B, Paquis-Flucklinger V, Grevent D, Edvardson S, Steffann J, Funalot B, Villeneuve N, Valayannopoulos V, de Lonlay P, Desguerre I, Brunelle F, Bonnefont JP, Rotig A, Munnich A, Boddaert N. A common pattern of brain MRI imaging in mitochondrial diseases with complex I deficiency. *J Med Genet* 2011; **48**(1): 16-23.
23. Leigh D. SUBACUTE NECROTIZING ENCEPHALOMYELOPATHY IN AN INFANT. *Journal of Neurology, Neurosurgery & Psychiatry* 1951; **14**(3): 216-21.
24. Rahman S, Blok RB, Dahl HHM, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thorburn DR. Leigh syndrome: Clinical features and biochemical and DNA abnormalities. *Annals of neurology* 1996; **39**(3): 343-51.
25. Diodato D, Ghezzi D, Tiranti V. The Mitochondrial Aminoacyl tRNA Synthetases: Genes and Syndromes. *Int J Cell Biol* 2014; **2014**: 787956.
26. Matthews L, Enzinger C, Fazekas F, Rovira A, Ciccarelli O, Dotti MT, Filippi M, Frederiksen JL, Giorgio A, Kuker W, Lukas C, Rocca MA, De Stefano N, Toosy A, Youssry T, Palace J. MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis. *Journal of neurology, neurosurgery, and psychiatry* 2014.
27. Yu-Wai-Man P, Spyropoulos A, Duncan HJ, Guadagno JV, Chinnery PF. A multiple sclerosis-like disorder in patients with OPA1 mutations. *Annals of clinical and translational neurology* 2016; **3**(9): 723-9.
28. Ahmed ST, Alston CL, Hopton S, He L, Hargreaves IP, Falkous G, Olahova M, McFarland R, Turnbull DM, Rocha MC, Taylor RW. Using a quantitative quadruple immunofluorescent assay to diagnose isolated mitochondrial Complex I deficiency. *Scientific reports* 2017; **7**(1): 15676.

29. Sazanov LA. A giant molecular proton pump: structure and mechanism of respiratory complex I. *Nat Rev Mol Cell Biol* 2015; **16**(6): 375-88.
30. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM. Mitochondrial diseases. *Nature reviews Disease primers* 2016; **2**: 16080.

ACCEPTED MANUSCRIPT

Figure Legend

Figure 1. Cranial and spine MRI. Axial T2-weighted view of Patient 1·2 showed hyperintensities involving the cortical and subcortical areas of left frontal lobe when she presented with the first stroke-like episode (A); the cranial MRI performed during the subsequent stroke-like episode showed hyperintensities involving the left parietal lobe and right cerebellar cortex, suggestive of cross cerebellar diaschisis (B) and extensive signal abnormalities in the brainstem (C, coronal view). Axial T2-weighted view of Patient 2 showed an isolated, left thalamic lesion (D). Axial T2 view (E) showed a discrete signal abnormality in the right cerebellum, and asymmetrical hyperintensities in the medulla in Patient 4. The sagittal T2 view (F) showed an anterior, long hyperintensity in the cervical cord spanning C2-6 levels in Patient 5, corroborated with the signal abnormalities shown in the axial view (G).

Figure 2. Heteroplasmy levels of the m.13094T>C mutation. (A) A negative correlation between age and blood mutant heteroplasmy level. (B) Distribution of mutant heteroplasmy levels for individual patient. The numbering of X-axis corresponds to the patient number of Table 1.

Figure 3. Neuropathological features of Patient 1.2 and 8. Patient 1.2: The posterior cerebellar cortex is affected by multiple necrotic lesions (demarcated by *) demonstrating atrophy of the molecular layer, Purkinje cell dropout and granule cell loss (A; LFB H&E) and total necrosis of the cortex and underlying white matter (B; LFB H&E). The basis pontis demonstrates a devastating lesion with total neuronal cell loss (C; red dashed line; LFB H&E). Scale bar = 100 microns.

Patient 8: The lower midbrain shows devastated inferior colliculus with prominent capillary proliferation (arrows), microvacuolation and severe neuronal cell loss (D; H&E). The thalamus (E; LFB H&E) and subthalamic nucleus (F; H&E) are devastated featuring

prominent capillary proliferation (arrows), microvacuolation, severe neuronal cell loss and morphologically normal neurons scattered throughout (arrowhead). The occipital lobes reveal microvacuolation and laminar necrosis of the cortical layers within Brodmann area 17 (G; LFB H&E) with the underlying white matter demonstrating myelin pallor relative to otherwise preserved myelin. The cortex features microvacuolation, severe neuronal cell loss and capillary proliferation. Surviving neurons within the inferior colliculus lack complex I subunit expression (H; NDUFB8 IHC, arrows) while mitochondrial mass is high (I; SDHA IHC, arrows).

Table Legend

Table 1. Syndromic classification and clinical features of individuals with the m.13094T>C mutation (n=24). *=deceased, AO= age of onset, AL= age of last follow up or death, B/L INO= bilateral inter-nuclear ophthalmoplegia, Dev delay= developmental delay (including motor and speech), F= female, HCM= hypertrophic cardiomyopathy, HTN= hypertension, LA= lactic acidosis, LS= Leigh syndrome, LVH= left ventricular hypertrophy, M= male, MELAS= mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, mths= months, n.d.= not done, NIV= non invasive ventilation, n.k.= not known, ON= optic neuropathy, PEG= percutaneous endoscopic gastrostomy, PFO= patent foramen ovale, PN= peripheral neuropathy, Psy= neuropsychiatric symptoms such as severe depression, anxiety or personality change, RF= respiratory failure, SCA= spinocerebellar ataxia, SLE= stroke-like episodes, yrs= years.

Table 2. Cranial MRI changes associated with the m.13094T>C mutation (n=17). All cortical lesions (including cerebellar cortex) exhibited restricted diffusion. B/L= bilateral, CR= corona radiata, F= frontal lobe, H= hippocampus, L= left, n.k.= not known, O= occipital lobe, P= parietal lobe, R= right, T= temporal lobe, U/L= unilateral, Δ= Patient 2·2 had a history of clinically and radiologically defined lacunar stroke (internal capsule and corona radiata), *= the extent of cervical lesion had not been clearly defined

Table 3. The m.13094T>C heteroplasmy levels in different postmortem tissues.

Figure 1




Fig. 1

Figure 2




Fig. 2




Fig. 3

Table Legend

Table 1. Syndromic classification and clinical features of individuals with the m.13094T>C mutation (n=24). *=deceased, AO= age of onset, AL= age of last follow up or death, Ap= apnoea, At= ataxia, B= blood, B/L INO= bilateral inter-nuclear ophthalmoplegia, Brady= bradycardia, Cog= cognitive impairment, Dev delay= developmental delay (including motor and speech), F= female, Fib= fibroblast, HCM= hypertrophic cardiomyopathy, HTN= hypertension, LA= lactic acidosis, LS= Leigh syndrome, LVH= left ventricular hypertrophy, M= male, MELAS= mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes, mths= months, Mu= muscle, n.d.= not done, NIV= non-invasive ventilation, n.k.= not known, ON= optic neuropathy, PEG= percutaneous endoscopic gastrostomy, PFO= patent foramen ovale, PN= peripheral neuropathy, Psy= neuropsychiatric symptoms such as severe depression, anxiety or personality change, Pt= ptosis, RF= respiratory failure, SCA= spinocerebellar ataxia, SLE= stroke-like episodes, Str= strabismus, Sz= seizures, trachy= tracheostomy, U= urine, yrs= years.

Pedigree	Relation	AO/ AL*	Syndrome	Clinical features												Heteroplasmy (%)			
				Sz	SL	Co	Str	ON	Pt	Ap	D	At	PN	LA	Cardiac	Other	B	U	Mu
1 (F)	Prob and	17/3 7*	LHON/ MELAS	+	+	+	-	+	-	-	-	+	+	-	-	-	0	5	n.
		2 mths / 9 mths															n.d.	n.	6
1.1 (M)	Offspring	* 9 mths	LS	-	-	n.k.	-	-	-	+	+	-	n.k.	+	-	-			
1.2 (F)	Offspring	10/1 4*	MELAS /LS	+	+	+	+	+	-	-	+	+	+	-	-		46	6	9
2 (F)	Prob and	12/3 0	SCA/M ELAS	+	+	+	-	-	+	-	-	+	+	-	-		9	4	3
2.1 (F)	Mother	n.k./ 49	Ataxia	-	-	-	-	-	-	-	-	+	-	-	-		3	2	n.
																	0	n.	n.
2.2 (F)	Maternal granddaughter	-/74	None	-	-	-	-	-	-	-	-	+	-	-	-	Ischaemic stroke, tremor		n.	n.
2.3 (M)	Maternal cousin	4 mths / 49	LS	n.k.	n.k.	n.k.	n.k.	n.k.	n.k.	n.k.	+	n.k.	n.k.	n.k.	n.k.		n.d.	n.	n.

	n	1.5*															29	n. d.	n. d.	
2-4 (M)	Maternal cousin	5/43	LS-like/SCA	-	-	-	+	+	-	-	-	+	-	-	-	-	-	76	8	8
3 (M)	Prob and	6 wks/ 5.4 mths*	LS	+	-	n. k.	+	-	+	+	+	-	-	+	-	-	19	4	n. d.	
3-1 (F)	Mother	- /20s	Unaffected	-	-	-	-	-	-	-	-	-	-	-	-	-	n.d.	n. d.	n. d.	
4 (M)	Prob and	4/6*	LS	-	-	-	+	-	+	+	+	+	-	Raised CS F	4	9	n. d.			
4-1 (F)	Mother	- /n.k.	Unaffected	-	-	-	-	-	-	-	-	-	-	HC M	n.d.	n. d.	n. d.			
5 (F)	Prob and	13/14*	MELAS /LS	+	+	+	+	-	+	+	-	-	+	Spasticity	n.d.	n. d.	n. d.			
6 (M)	Prob and	2.25 /3*	LS	-	-	n. k.	+	-	+	+	+	+	-	Brady	45	n. d.	n. d.			
7 (M)	Prob and	7/21	LHON	-	-	-	-	+	-	-	-	-	-	-	26	n. d.	n. d.			
7-1 (M)	Brother	6/20	Subclinical ON	-	-	-	-	+	-	-	-	-	-	-	35	n. d.	n. d.			
7-2 (F)	Mother	- /47	Unaffected	-	-	-	-	-	-	-	-	-	-	-	7	n. d.	n. d.			
8 (F)	Prob and	34/35*	MELAS /LS	+	+	+	+	-	+	-	-	+	-	PF O	n.d.	n. d.	n. d.			
8-1 (F)	Mother	- /70s	Unaffected	-	-	-	-	-	-	-	-	-	-	-	0	6	n. d.			
9 (F)	Prob and	27/34	MELAS	+	+	+	-	-	-	-	-	+	-	-	5	n. d.	n. d.			
10 (M)	Prob and	22/24	LS	-	-	-	+	-	+	+	-	+	-	LV H	38	n. d.	n. d.			
11 (M)	Prob and	2/30	LS	-	-	-	+	+	-	+	-	+	-	Raised CS F	n.d.	n. d.	n. d.			
12 (M)	Prob and	1/4	LS	-	-	-	+	-	+	-	+	-	-	Trachy, PEG	49	n. d.	n. d.			
13 (M)	Prob and	1/14*	LS	+	-	+	+	-	+	+	+	n. k.	-	+	-	49	n. d.	n. d.		
				8/2	6/23	7/2	11/3	6/3	10/3	9/4	6/3	12/2	3/2	9/2	4/2					
				3	23	0	3	3	3	4	3	2	2	3	2					

Table 2. Cranial MRI changes associated with the m.13094T>C mutation (n=17). All cortical lesions (including cerebellar cortex) exhibited restricted diffusion. B/L= bilateral, CR= corona radiata, F= frontal lobe, H= hippocampus, L= left, n.k.= not known, O= occipital lobe, P= parietal lobe, R= right, T= temporal lobe, U/L= unilateral, Δ= Patient 2:2 had a history of clinically and radiologically defined lacunar stroke (internal capsule and corona radiata), *= the extent of cervical lesion had not been clearly defined

Patient no	Age at scan (Years)	Brain imaging anomalies										Fluctuating/relapsing/remitting imaging changes
		Cerebral cortex	Basal ganglia	Thalamus	Cerebellum	Brainstem					Cervical cord	
		Stroke-like lesion			Dentate nuclei	Cortex	Atrophy	Midbrain	Pons	Medulla		
1	36	P, T (R)	-	U/L (R)	-	-	+	-	-	-	-	Yes
1.1	8 mths	-	-	B/L	-	-	-	+	+	+	C1-2	n.k.
1.2	13; 14	P, O, H (L)	-	B/L	+	+	+	+	+	+	C1	Yes
2	26; 30	O (R)	-	U/L (L)	-	-	-	-	-	-	-	Yes
2.2	66	Δ	-	-	-	-	-	-	-	-	-	No
2.4	31	-	-	B/L	+	+	+	+	+	+	-	n.k.
3	3 mths	-	-	B/L	-	-	-	+	+	+	+	n.k.
4	6	-	-	-	+	-	-	+	-	+	-	n.k.
5	13; 14	F (B/L), P (B/L)	-	B/L	-	+	+	+	+	-	C2-6	Yes
6	2.25	-	-	B/L	-	-	-	+	+	+	-	No
7	7	-	-	-	-	-	-	-	-	-	-	n.k.
8	33	O (R)	-	B/L	-	-	-	+	-	-	-	Yes
9	34	O (B/L), P, T, F (L)	-	-	-	-	-	-	-	-	n.k.	Yes
10	24	-	-	-	-	-	-	+	+	+	-	n.k.
11	22, 23 1 yr 4 mths	-	+	U/L	-	-	+	+	+	+	+	Yes
12	10	-	-	B/L	-	-	-	+	+	+	n.k.	Yes
13	10	-	+	B/L	-	-	-	+	+	-	-	No
Total		6/17	2/17	12/17	3/17	3/17	5/17	12/17	10/17	9/17	5/15	8/11

Table 3. The m.13094T>C heteroplasmy levels in different post-mortem tissues.

	Patient 1.2	Patient 8	Patient 13
Syndrome	MELAS/LS	MELAS/LS	LS
Age of death	14	35	14
Post-mortem tissues			
Heart	75%	-	64%
Adrenal Gland	96%	-	-
Liver	83%	-	23%
Kidney	83%	-	56%
Bladder	90%	-	
Skeletal muscle	88%	-	52%
Intestine	69%	-	24%
Lung	-	-	28%
Frontal lobe	69%	47%	-
Hippocampus	67%	52%	-
Cerebellum	64%	58%	-

Highlights

- The m.13094T>C mutation in *MT-ND5* is associated with severe, variable neurological manifestations.
- Whole mtDNA genome sequencing should be considered in patients with undiagnosed complex neurological disorders.

ACCEPTED MANUSCRIPT